NITI Aayog Unveils Comprehensive 2047 Roadmap to Globalize Ayurveda and Boost Exports
15-Jul-26 08:03:36
.jpeg)
New Delhi: In a historic move to transition traditional Indian medicine from fragmented wellness therapies to a mainstream, scientifically validated global healthcare system, NITI Aayog has officially released its landmark report titled "Strategic Roadmap for Making Ayurveda Global."
Prepared by the Health Division of NITI Aayog in collaboration with PricewaterhouseCoopers (PwC), the blueprint outlines a meticulous, phased strategy aligning with the Viksit Bharat@2047 vision. The overarching goal is to achieve formal integration and regulatory recognition for Ayurveda in at least 20 national health systems across the globe by 2047.
Bridging the Global Workforce Gap: The Global Ayurveda Register (GAR)
The report highlights a significant paradox in the current ecosystem: while India possesses a robust internal framework with over 355,000 certified practitioners, nearly 95% of this highly qualified workforce remains concentrated within domestic borders. This stark imbalance points to severe restrictions in international mobility.
To address these professional bottlenecks, NITI Aayog has recommended:
-
Global Ayurveda Register (GAR): A standardized, digital credentialing and Continuous Professional Development (CPD) registry aligned with World Health Organization (WHO) standards to ease international licensing.
-
World Federation for Ayurveda and Yoga: The creation of an apex global body to uniformize educational, training, and clinical standards across borders.
-
International Medical School Electives: Introducing specialized Ayurveda electives and micro-credentials into global medical curricula to expand academic integration.
This systemic structural shift will directly enhance the international authority of modern Ayurveda education, paving the way for easier overseas licensing for graduates.
Boosting Trade: From Dietary Supplements to Prescription Medicines
The economic data compiled in the report shows steady growth, with international exports rising consistently from USD 1.09 billion in 2014 to USD 2.16 billion in 2023, spanning nearly 150 countries. However, NITI Aayog notes that due to complex regulatory barriers, the vast majority of these exports are still labeled and sold merely as "dietary supplements" rather than high-value finished medicines.
To shift from raw-material dependency to premium clinical trade, the roadmap pitches the development of an export-focused Ayurvedic Pharmacopoeia alongside a real-time Ayush trade dashboard to track international market trends. Furthermore, it emphasizes upgrading domestic manufacturing facilities to strict WHO-GMP (Good Manufacturing Practices) norms to establish absolute quality compliance.
A Phased Prescriptive Vision to Rival Traditional Chinese Medicine (TCM)
Throughout the blueprint, NITI Aayog explicitly benchmarks the globalization trajectory of Ayurveda against Traditional Chinese Medicine (TCM), which enjoys significantly higher international integration and insurance coverage. By implementing multi-country clinical trials via WHO Collaborating Centres and aggressively promoting Medical Value Travel (MVT) through bundled Ayush Visa packages, India aims to dismantle global skepticism regarding scientific evidence.
Commenting on the release, NITI Aayog Vice Chairman Shri Ashok Kumar Lahiri stated that the globalization framework presents an unprecedented opportunity to position India as the absolute leader in traditional medicine while unlocking immense economic value.
Adding to this, Ministry of Ayush Secretary Vaidya Rajesh Kotecha reaffirmed that these strategic guidelines will powerfully complement the ministry’s ongoing initiatives to turn Ayurveda News from localized wellness updates into globally tracked medical breakthroughs.